What Isomorphic Labs does
Isomorphic Labs is an AI-first drug design and digital biology company focused on accelerating drug discovery “from first principles” using proprietary frontier machine-learning models. The company positions its core capability as a unified drug design engine, called IsoDDE, intended to support multiple therapeutic areas and drug modalities (including small molecules and biologics) by combining predictive and generative modeling for biomolecular systems. Isomorphic Labs’ broader strategy centers on (1) building scalable computational methods and infrastructure for in-silico exploration, (2) applying those methods end-to-end within a drug-design workflow, and (3) validating impact through partnerships with pharmaceutical companies as well as internal programs.
Operationally, Isomorphic Labs is structured as an Alphabet subsidiary. It has offices in London, Lausanne, and Cambridge (Massachusetts), and it describes itself as operating across partnered programs and wholly-owned internal pipeline programs. Its publicly described differentiation includes a “unified” multi-modality design engine, a curated “dataverse” intended to power large-scale in-silico experiments at scale, and model improvements framed as moving beyond structure prediction toward drug-discovery-relevant predictive accuracy (for example, protein–ligand and antibody–antigen modeling, binding-affinity prediction, and generalization to novel/unseen biomolecular systems).